"目录号: HY-13673
Goserelin(ICI 118630)是注射型促性腺激素释放激素（GnRH）超激动剂。
相关产品
Degarelix-Leuprolide Acetate-Alarelin Acetate-Goserelin acetate-Triptorelin-Nafarelin-Deslorelin-Relugolix-Abarelix-Cetrorelix Acetate-Elagolix-Gonadorelin acetate-Lecirelin-Buserelin Acetate-
生物活性
Description
Goserelin(ICI 118630) is an injectable gonadotropin releasing hormone superagonist (GnRH agonist).IC50 value:Target: GnRH agonistGoserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. It may also be used in the treatment of male-to-female transsexuals and is favoured above other anti-androgens in some countries, such as the UK. It is available as a 1-month depot and a long-acting 3-month depot. Goserelin stimulates the production of the sex hormones testosterone and estrogen in a non-pulsatile (non-physiological) manner.
Clinical Trial
National Cancer Center, Korea
Metastatic Breast Cancer
October 2005
Phase 2
M.D. Anderson Cancer Center
Breast Cancer
August 2006
Phase 3
AstraZeneca
Breast Cancer
February 2006
Phase 2
AstraZeneca
Advanced Breast Cancer
April 2006
Phase 2
Ontario Clinical Oncology Group (OCOG)-AstraZeneca
Prostate Cancer
April 2007
Phase 3
AstraZeneca
Breast Cancer-Ovarian Function
Phase 3
Hospital Affiliated to Military Medical Science, Beijing
Metastatic Breast Cancer
January 2014
Phase 2
Ramathibodi Hospital-AstraZeneca
Spinobulbar Muscular Atrophy-Kennedy's Disease
April 2008
Phase 4
Zhejiang Cancer Hospital
Mammography-Estrogen-Lipemia-Endometrium-Ultrasonography
June 2008
Ferring Pharmaceuticals
Prostate Cancer
October 2010
Phase 3
Samsung Medical Center-Asan Medical Center-Seoul National University Hospital-Severance Hospital-Ulsan University Hospital-Kosin University Gospel Hospital-Korea University Guro Hospital-Korea University Anam Hospital
Metastatic Breast Cancer-Estrogen Receptor Positive Tumor-Breast Cancer Nos Premenopausal
December 2010
Phase 2
UNICANCER
Prostate Cancer
October 2006
Phase 3
Ferring Pharmaceuticals
Prostate Cancer
June 2009
Phase 3
Spectrum Pharmaceuticals, Inc
Prostate Cancer
November 2010
Phase 2
German Breast Group
Breast Cancer
March 2005
Phase 2
Speciality European Pharma Limited
Prostate Cancer
January 1999
Phase 3
Astellas Pharma Inc
Prostate Cancer
August 2013
Phase 3
National Cancer Institute (NCI)
Estrogen Receptor Positive-HER2/Neu Negative-Recurrent Breast Carcinoma-Stage IIA Breast Cancer-Stage IIB Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer
January 2013
Phase 2
University of Sao Paulo
Uterine Leiomyoma
January 2013
Phase 4
Zhejiang University
Endometriosis
March 2008
Phase 4
Southwest Oncology Group-National Cancer Institute (NCI)
Breast Cancer
September 2005
Phase 2
New York University School of Medicine-National Cancer Institute (NCI)
Breast Cancer
June 2000
Phase 2
Ferring Pharmaceuticals
Prostate Cancer
August 2009
Phase 3
Ferring Pharmaceuticals
Prostate Cancer
April 2009
Phase 3
Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)
Fallopian Tube Cancer-Ovarian Cancer-Primary Peritoneal Cavity Cancer
September 2000
Phase 2
Vanderbilt-Ingram Cancer Center
Metastatic Breast Cancer
Phase 1
Ferring Pharmaceuticals
Prostate Cancer
April 2009
Phase 3
Washington University School of Medicine-National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer-HER2-negative Breast Cancer-Stage II Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer
September 2011
Phase 2
Southwest Oncology Group-National Cancer Institute (NCI)-Cancer and Leukemia Group B-Eastern Cooperative Oncology Group-International Breast Cancer Study Group
Breast Cancer-Infertility-Menopausal Symptoms
October 2003
Phase 3
National Cancer Institute (NCI)
Prostate Adenocarcinoma-Stage IIA Prostate Cancer-Stage IIB Prostate Cancer
July 9, 2010
Phase 1-Phase 2
Institute of Cancer Research, United Kingdom-National Cancer Institute (NCI)
Breast Cancer
March 2000
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
May 1987
Phase 3
H. Lee Moffitt Cancer Center and Research Institute-Novartis
Breast Cancer-Breast Cancer - Female-Breast Cancer - Male
February 15, 2016
Phase 1
National Cancer Institute (NCI)
Recurrent Prostate Cancer
June 2006
Phase 2
University of Tampere
Prostate Cancer
October 2004
Phase 4
Peking Union Medical College Hospital
Breast Cancer-Chemotherapy Induced Amenorrhea-Ovarian Function Suppression
May 2014
Phase 3
AstraZeneca
Breast Cancer
December 2001
Phase 2
Austrian Breast & Colorectal Cancer Study Group
Early-Stage Breast Cancer
December 1990
Phase 3
Ferring Pharmaceuticals
Prostate Cancer
January 2013
Phase 3
Mayo Clinic-National Cancer Institute (NCI)
Prostate Adenocarcinoma-Stage IIA Prostate Cancer-Stage IIB Prostate Cancer-Stage III Prostate Cancer-Stage IV Prostate Cancer
July 2009
Phase 2
Stanford University-AstraZeneca
Breast Cancer
October 2000
Endo Pharmaceuticals
Prostate Cancer-Adenocarcinoma of the Prostate
May 2000
Phase 3
Novartis Pharmaceuticals-Novartis
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
February 4, 2015
Phase 1
National Cancer Institute (NCI)
Prostate Adenocarcinoma-Recurrent Prostate Carcinoma-Stage IV Prostate Cancer
December 2010
Phase 2
AstraZeneca
Breast Cancer
October 2007
Phase 3
Peking Union Medical College Hospital
Breast Cancer
June 2015
Phase 3
AstraZeneca
Metastatic Prostate Cancer
August 2004
Phase 4
Vanderbilt-Ingram Cancer Center-National Cancer Institute (NCI)
Breast Cancer
August 2009
Phase 2
Korean Breast Cancer Study Group
Breast Cancer
